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 Ewing sarcoma is a malignant disease of young people that arises most 
frequently in bones of the femur and pelvis.  The disease most often afflicts 
adolescents, creating physical, emotional, and developmental challenges during 
an individual’s most formative years.  Mainstays of therapy include surgery and 
chemotherapy, meaning that survival may come at very high costs – amputation 
and lifelong disability.  Those who suffer metastasis or relapse must confront a 
poor prognosis.  This is due in part to a lack of effective therapeutic options capable 
of destroying cancer at the cellular and molecular levels.  To this end, molecular 
research continues to pursue greater understanding of the underlying biology of 
these tumors. 
 The principal genetic lesion in Ewing sarcoma is a translocation that fuses 
chromosomes 11 and 22, giving rise to an oncogenic fusion protein known as 
EWS/FLI.  EWS/FLI causes massive transcriptional misregulation, generating a 
gene expression program that transforms cells into cancer.  Studies of 
transcriptional consequences of EWS/FLI misregulation have identified numerous 
genes that are necessary – but not sufficient – for tumorigenesis of Ewing 
sarcoma.  These efforts have produced several candidates for molecular therapies 
for this malignancy, but no new therapies have yet reached the clinic.   
 Research continues this pursuit, and hope persists.  The work presented in 





underpinnings of Ewing sarcoma.  Specifically, these data provide preliminary 
insights into the effects that EWS/FLI has on misregulating metabolism, generating 
a program of biosynthesis that promotes and/or contributes to oncogenesis in 
these tumors.  Numerous metabolic pathways are altered upon silencing of 
EWS/FLI, suggesting that EWS/FLI drives expression changes of key enzymes 
involved in metabolic processes.  These data appear to indicate that generating a 
pro-oncogenic metabolic program is a key part of how EWS/FLI drives 
oncogenesis.   Due to the fact that metabolic enzymes are generally amenable to 
pharmacological modulation, these findings offer new hope to the pursuit of a 
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In the novel Frankenstein, Mary Shelley wrote, “None but those who have 
experienced them can conceive of the enticements of science” (1).  It may have 
been meant ironically in the novel, but the sentiment rings true to me.  My first 
experiences with “the enticements of science” occurred when I was a young boy.  
One year, I was given a microscope for my birthday, and I went about observing 
the various tiny creatures that lived in the creek that ran through my back yard.  I 
also looked at blood, insects, textiles, and anything else I could think of.  I became 
fascinated with the microscopic world.  In later years, I was given toys of electronic 
circuits, Lego kits, toy rockets, airplanes, and others – all of which helped me to 
learn creativity and problem solving.  I am thankful to my parents, grandparents, 
aunts, and uncles for the many ways that they encouraged my curiosity and 
creativity, and helped foster my appreciation of science.  
 Later, as I started college, I came to know Dr. J. David Symons, and 
received my first experiences in University-level scientific investigation.  His 
mentorship and support kindled an interest in research that prompted me to pursue 
a dual degree program as an MD/PhD student.  It was after joining the MD/PhD 
program at the University of Utah that I was introduced to mentors like Dr. Dean Li 
and Dr. Jerry Kaplan, and I began to appreciate and strive for scientific rigor. 
 As I began my graduate studies, I was privileged to work with and be taught 
 xii 
 
by Dr. Stephen Lessnick. As a member of his lab, I learned many unforgettable 
and formative lessons about science, as well as the intrigues of academic 
medicine.  I am grateful to Dr. Lessnick for the opportunities he offered me, and 
for giving me the freedom and independence that set me on a path toward being 
an autonomous, self-directed scientist.  I spent three years in the Lessnick Lab, 
and the training I received there laid the groundwork for my continuing 
development as a scientist. 
 I have been fortunate to have many other mentors, as well.  They have each 
taught me foundation-forming lessons.  I am particularly grateful to the members 
of my advisory committee, both past and present: Dr. Sheri Holmen, Dr. Sunil 
Sharma, Dr. Mike Engel, Dr. Brad Cairns, Dr. Janet Lindsley, and Dr. Adam 
Hughes.  Without the support and guidance from these individuals I would not have 
been able to complete the work presented in this dissertation.   
 I am also exceedingly thankful for the support of Dr. Jared Rutter.  After 
three years of studying in the Lessnick Lab, it was announced that the lab would 
be relocating.  I was invited to move with the lab, and I am grateful for Dr. 
Lessnick’s invitation and offers of continued support.  Nevertheless, for many 
reasons, I decided that I would not move with the lab, and so I needed to join a 
different research group.  Dr. Rutter offered to take me under his wing and continue 
my training, and he gave me the opportunity to join his lab.  (It should be noted 
that Dr. Holmen also offered me a position in her lab, and I am also very grateful 
to her for that.  These invitations meant very much to me during a personally 
difficult time of self doubt and shaken confidence.)   
 xiii 
 
In Dr. Rutter’s lab, I began studying cellular metabolism of stem cells and 
cancer.  I was immersed in high-level scientific debate and discussion.  The 
mentorship that I received from Dr. Rutter, and others in his lab, has enhanced my 
critical thinking skills, helping me to question my assumptions and seek out 
rigorous scientific evidence.  I am especially grateful to Dr. Rutter for allowing me 
the freedom to explore projects beyond the primary focus of the lab, which 
provided many lessons on the challenges of pursuing a project independently.   
I am particularly appreciative of the close personal support and mentorship 
given to me by my fellow MD/PhD students: Dr. John Schell, Dr. Kris Olson, and 
Claire Bensard (MD/PhD Candidate).  I never cease to be impressed by them and 
their sharp aptitudes for science and medicine, as well as the core altruism that 
guides them.  It is an honor to call them colleagues and friends, and I have been 
truly uplifted by working so closely with them. 
Additionally, I must attempt to express the depths of my appreciation to my 
friends and family.  My wife, Dr. Windy Tanner, has been an example of strength, 
tenacity, and dedication.  Through all of my struggles, I am thankful for her 
enduring love and support.  In spite of having gone through her own challenges, 
she has somehow found the time and energy to support me through mine.  She 
has been my partner throughout, providing comfort, love, and kindness.  My 
daughters, Charlotte and Kate, are my role models.  They are so smart, so 
inquisitive, so kind, and so fun-loving that I strive to emulate them.  They are a 
genuine reminder to me of the meaning of unfailing and unconditional love.   
I also must acknowledge my good friend Ben Robertson (for occasionally 
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getting me out of the lab and into the mountains) and my many friends and 
colleagues at Salt Lake County Search & Rescue, who persistently demonstrate 
true integrity, heroism, and dedication.  It has been an honor to serve alongside 
such selfless and devoted individuals. 
Finally, I wish to acknowledge the many sources of funding without which 
this work would not have been possible, including the National Institutes of Health, 
the National Cancer Institute, the Huntsman Cancer Foundation, and the Howard 
Hughes Medical Institute.  Special thanks to the core facilities of the University of 
Utah, particularly the High-Throughput Genomics core, the Bioinformatic Analysis 
core, and the Metabolomics core. 
I have been truly fortunate to have interacted with so many amazing 
individuals, and I am better for having known all of them.  I hope to live up to the 
principles instilled in me by having associated with all of these people during the 
past several years.   
 
1. M. W. Shelley, Frankenstein, or, The modern Prometheus (Broadview 








1.1 The Roaring Twenties 
  
 The second decade of the twentieth century was an era of cultural, social, 
and scientific dynamism.  Major advances in physics, chemistry, and biology – 
discoveries that would not merely change their field, but the entire world – burst 
forth during these years.  Much of the foundation of modern science and medicine 
was being established, creating the platform upon which we could firmly build our 
current and future understanding. 
 In this single decade: insulin was discovered and first used to treat diabetes; 
hydrocodone was first synthesized; epidural anesthesia was invented; the 
existence of macromolecules was first proposed; vitamins D & E were discovered; 
vaccines against diphtheria and pertussis were invented; the Pauli exclusion 
principle and the Heisenberg uncertainty principle were first described; the first 
human electroencephalogram was performed; the “Big Bang” theory was first 
described; covalent bonding of atoms was first proposed; penicillin was 
discovered; and the existence of DNA was proven.  Much of our current 
understanding of the realities of our universe began in the 1920s.  And immersed 
in this lively atmosphere of scientific advancement, in 1921, a New York 




come to bear his name.   
 
1.2 Diffuse Endothelioma of Bone 
 
James Ewing, the third son of a prominent Pittsburg judge, received an MD 
from the College of Physicians of New York, where he acquired an interest in 
histology and pathology.  He later taught at Cornell University, and became the 
Medical College’s first professor of pathology.  His position at Cornell enabled him 
to pursue various avenues of research at the New York Memorial Hospital (now 
known as Memorial Sloan-Kettering Cancer Center) where he offered the first 
descriptions of a “diffuse endothelioma of bone” (1).  He recognized that these cells 
exhibited morphological characteristics that distinguished them from other bone 
cancers and lymphomas.  In 1921, he wrote: 
For some years I have been encountering in material curetted from bone 
tumors a structure which differed markedly from that of osteogenic sarcoma, 
was not identical with any known form of myeloma, and which had to be 
designated by the vague term ‘round cell sarcoma’ of unknown origin and 
nature (1). 
 
These tumors quickly became known as “Ewing’s” sarcoma, with case 
reports being published as early as 1927 (2).  (While originally named using the 
possessive form “Ewing’s” sarcoma, current World Health Organization guidelines 
avoid possessive nomenclature; hence, “Ewing” sarcoma is the term utilized 
herein.) 
Ewing became well known and much respected as a cancer scientist.  His 
portrait was printed on the cover of Time magazine in 1931 with the subtitle 
“Cancer Man Ewing” (3).  He was a firm proponent of using radioactivity to treat 




therapy.  Radiotherapy and surgery were the mainstays of treatment for much of 
the first half of the twentieth century, but the advent of chemotherapeutic agents 
would later supplant radiation therapy in the efforts to treat patients with these 
tumors (4,5).  The therapeutic landscape continued to evolve, and the 
understanding of the true molecular roots of cancer continued to grow. 
I was not until the late twentieth century (many years after Ewing’s death in 
1943) that other scientists discovered the cytogenetic abnormalities responsible 
for tumorigenesis in Ewing sarcoma.  Their work would reveal that these tumors 
are driven by chromosomal translocations that generate fusion proteins with 
neomorphic functions and oncogenic consequences.  These translocations and 
our current understanding of their role in producing Ewing sarcoma are discussed 
in Chapter 2 and Chapter 3 of this dissertation. 
 
1.3 The Fermentation of Tumors 
 
 The scientific enlivenment of the 1920s was, of course, not confined to the 
United States.  Six years after James Ewing first published his description of 
“diffuse endothelioma”, a German scientist named Otto Warburg published a paper 
raising questions of cancer metabolism (6).  Ewing and Warburg were 
contemporaries, and co-contributors to publications in cancer science.  (It is 
perhaps interesting to note that Otto Warburg is also named in the 1931 Time 
Magazine article about James Ewing.)  Warburg wrote in 1927, “The fermentation 
of tumors was first found with cut pieces of tumor in vitro,” and asked “whether 
tumor cells in living animals can be killed off through lack of energy” (6).  Warburg 




formation, and maybe even a cause of cancer.  These were the first observations 
of a set of hallmark metabolic characteristics of cancer that have only recently 
begun to be understood, known today as the Warburg effect. 
 Based on his experiments assessing glucose consumption in rat tumors, 
Warburg theorized that tumor cells were incapable of effective respiration.  
However, as it became possible to isolate mitochondria from cancer cells and test 
their respiratory capacity, researchers discovered that respiratory proteins were 
not defective in cancer cells.  As techniques in genetics gained momentum, and 
mutations in oncogenes and tumor suppressors were discovered, the study of the 
role of metabolic alterations in tumorigenesis fell out of favor.   
 Nevertheless, seminal findings leading into the twenty-first century have just 
recently reignited the field of cancer metabolism.  Instead of altering metabolism 
for energetic purposes, it is now accepted that tumor cells shift metabolism into a 
more glycolytic state for the purpose of generating precursors for the biosynthetic 
processes that are necessary for rapid growth and proliferation (7).  Techniques in 
biochemical analysis have become increasingly sophisticated, and it is now 
possible to assess the flux through metabolic pathways with great accuracy and 
resolution (8–10).  One such study, tracing atoms from precursor molecules and 
assessing their contribution to cellular mass, is briefly discussed in Chapter 4.  
 
1.4 Ewing and Warburg Converge 
  
Although it is doubtful whether the two ever met, the work of James Ewing 
and Otto Warburg has begun to converge nearly 100 years after they first 




rearrangement – a decidedly genetic event – little attention has been focused on 
metabolic derangements that may play a role in these tumors.   
 Considering that Ewing sarcoma behaves similarly to other cancers, it is not 
unreasonable to hypothesize that these tumors harbor metabolic aberrations 
similar to those seen in other cancers.  However, since Ewing sarcoma is 
principally driven by a single genetic mutation (a chromosomal translocation that 
generates a fusion protein known as EWS/FLI) it provides a uniquely “clean” 
system in which metabolic processes of cancer can be studied without the potential 
confounding influence of numerous other genetic mutations.  Determining what 
metabolic changes are induced by EWS/FLI could shed light on the oncogenic role 
that such metabolic changes may have in Ewing sarcoma, and perhaps in many 
other tumors as well.  Our work on this front is presented in Chapter 5 of this 
dissertation. 
 
1.5 A Continuing Crusade 
 
 Despite having distinct backgrounds and interests, Ewing and Warburg 
shared a common goal: to cure cancer.  We continue to pursue this goal today.  
Ewing sarcoma remains a devastating disease of young people.  It threatens their 
lives and takes their limbs.  Survival often comes only at the severe cost of 
amputation and lifelong disability.  Although some go on to live fulfilling lives, others 
are not so fortunate.  The methods of scientific inquiry have seldom, if ever, been 
exercised in pursuit of a more laudable objective than curing childhood cancer.   
 While much remains to be done, and success is not guaranteed, we can 




and others.  Scientists with aggressive curiosity and tenacious enthusiasm will 
continue to make breakthroughs, and cancer will progressively become more 
manageable.  It is hoped that the work presented herein will make some small 
contribution toward these efforts, or that they will – at minimum – provoke thought 




1.  Ewing J. Diffuse endothelioma of bone. Proc N Pathol Soc. 1921;21:17.  
 
2.  Pritchard JE. Ewing’s sarcoma: a report of a case. Can Med Assoc J. 1927 
Oct;17(10 Pt 1):1164–7.  
 
3.  TIME Magazine Cover: Professor James Ewing - Jan. 12, 1931 [Internet]. 
TIME.com. [cited 2017 May 15]. Available from: 
http://content.time.com/time/covers/0,16641,19310112,00.html 
 
4.  Lee ES. Treatment of bone sarcoma. Proc R Soc Med. 1971 
Dec;64(12):1179–80.  
 
5.  Rosen G, Caparros B, Mosende C, McCormick B, Huvos AG, Marcove RC. 
Curability of Ewing’s sarcoma and considerations for future therapeutic 
trials. Cancer. 1978 Mar;41(3):888–99.  
 
6.  Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J 
Gen Physiol. 1927 Mar 7;8(6):519–30.  
 
7.  Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark 
even Warburg did not anticipate. Cancer Cell. 2012 Mar 20;21(3):297–308.  
 
8.  Niklas J, Schneider K, Heinzle E. Metabolic flux analysis in eukaryotes. Curr 
Opin Biotechnol. 2010 Feb;21(1):63–9.  
 
9.  Wiechert W. 13C metabolic flux analysis. Metab Eng. 2001 Jul;3(3):195–
206.  
 
10.  Zamboni N. 13C metabolic flux analysis in complex systems. Curr Opin 







































Reprinted with permission of Springer Publishing International.   
 
Chromosomal Translocations and Genomic Rearrangements in Cancer, p. 333-354 








































































DETERMINING GENOME-WIDE LOCALIZATION 
 







 The EWS/FLI fusion protein is the main oncogenic driver of Ewing sarcoma.  
Containing the transcriptional regulatory domain of EWSR1 fused to the DNA-
biding domain of FLI1, it functions as an aberrant transcription factor that alters the 
expression of several thousand genes.  The result is an oncogenic phenotype that 
arises primarily in adolescents.  Transcription profiling of Ewing sarcoma cells has 
been well characterized, and numerous targets have been identified as necessary, 
but not sufficient, for Ewing sarcoma tumorigenesis.  Binding of EWS/FLI is 
associated with activation of some genes, and repression of others.   However, the 
mechanisms utilized by EWS/FLI to induce such widespread transcriptional 
misregulation are not completely understood.  It is hypothesized that EWS/FLI 
function is partly determined by its localization and ability to co-opt or disrupt 
regulatory factors normally involved in transcriptional regulation of distinct loci.  
This chapter presents preliminary data aimed at addressing such questions by 
assessing localization of EWS/FLI and its partners genome wide.  We performed 




of localization changes that result from deleting portions of the EWS/FLI fusion 
protein.  These studies are being continued by the Lessnick Lab at Nationwide 




Ewing sarcoma is the second most common bone-associated tumor in 
children and adolescents, arising most frequently in the bones of the pelvis and 
femur (1).  It is a relatively rare tumor, accounting for approximately 300 new 
diagnoses each year in the United States (2).  Currently, therapeutic protocols rely 
mainly on surgical resection and adjuvant chemotherapy.  And these approaches 
are remarkably efficacious, achieving 5-year survival rates approaching 90% (1,3–
5).  Nevertheless, patients who encounter metastasis or relapse of their disease 
have a poorer prognosis, with 5-year survival rates approaching 15% (1,6).  
Accordingly, there is a substantial need for novel therapeutic strategies targeting 
this cancer on the cellular and molecular level. 
The primary molecular lesion responsible for tumorigenesis in Ewing 
sarcoma is a chromosomal translocation event between chromosomes 11 and 22, 
resulting in fusion of the EWSR1 and FLI1 genes (7–10).  The in-frame fusion of 
these genes produces an aberrant protein known as EWS/FLI (EF).  This protein 
contains the C-terminal transcriptional regulatory domain of EWSR1 joined to the 
DNA-binding domain of FLI1.  Thus, EF is an aberrant transcription factor capable 
of altering gene expression across the genome.  Indeed, the transcriptional 
misregulation driven by EF has been well characterized via both microarray and 




Genome-wide localization of EF is an active area of study.  Chromatin 
immunoprecipitation (ChIP) studies have been employed with microarrays (ChIP-
on-ChIP) and high-throughput DNA sequencing (ChIP-Seq) to reveal that EF binds 
at canonical FLI1 binding sites, as well as sites for other ETS-family transcription 
factors (19–22).  Interestingly, these studies have also shown that EF has a 
propensity to bind at regions of GGAA repeats, including near promoters of genes 
whose expression is altered by EF.   
EF has also been shown to interact with regulatory complexes such as the 
nucleosome remodeling and deacetylase (NuRD) complex in order to repress 
expression of certain EF target genes (23).  Additional epigenetic regulatory 
enzymes have also been shown to play important roles in Ewing sarcoma biology 
(24,25).  Such evidence has led to the hypothesis that EF utilizes or hijacks a 
relatively small number of regulatory processes to alter chromatin state and 
subsequent gene transcription.  Rather than employing a unique mechanism for 
each gene it alters, it is more likely that EF alters numerous genes via one or two 
mechanisms (or variations on one or two mechanistic themes).  To this end, 
current work aims to better determine genome-wide localization of EF and its 
partners, with particular interest in assessing the mechanisms regulating EF 
localization.  Specifically, we sought to determine whether deletion of certain 
functional portions of the EF protein would alter its ability to bind at promoters of 
target genes, and/or affect its interactions with regulatory partners.   
The work presented in this chapter represents a portion of the initial efforts 




our preliminary ChIP-seq analyses for EF, as well as for the chromatin binding 
factor CTCF.  The remainder of this investigation is being continued by the 




3.3.1 ChIP-Seq of EF reveals numerous EF-bound  
 
loci across the genome 
 
 We performed ChIP experiments for EF in A673 cells, followed by high-
throughput DNA sequencing.  EF-bound loci were identified throughout the 
genome (Figure 3.1A).  A total of 22,406 EF-bound sites were identified using a 
threshold Log2(ratio) of ≥ 0.585 and an AdjP value of ≥ 10.  While many binding 
sites were located in intergenic regions, there was a prominent clustering of EF-
bound loci within 1 kb of transcription start sites (Figure 3.1B).  Indeed, the read 
count frequency was highest near the TSS (Figure 3.1C).  This is consistent with 
the known role that EF has in transcriptional misregulation in Ewing sarcoma, and 
suggests that EF may alter transcription of numerous genes by binding near or 
within their promoter regions. 
 
3.3.2 EF binds both high-affinity ETS sites  
 
and GGAA microsatellite repeats 
 
 The ETS (E26 transformation specific) family of transcription factors all 
contain a winged helix-turn-helix domain (known as the ETS domain) that binds 
with high affinity to DNA motifs containing a core sequence of GGAA or GGAT.  




is ACCGGAAGTG (26–28). 
Consistent with previous work (19,20,29), we found that EF was present at 
binding sites for ETS-family transcription factors (Figure 3.2).  Additionally, EF 
binding was detected at GGAA microsatellite repeats, including loci upstream of 
genes known to be altered by EF (Figure 3.3).  Interestingly, EF-bound 
microsatellites could be found near both upregulated and downregulated targets 
of EF, suggesting distinct mechanisms of transcriptional activation versus 
transcriptional repression, beyond the mere presence of EF. 
 
3.3.3 Increased gene expression is more common  
when EF binds nearby GGAA  
microsatellite repeats 
 ChIP-seq data were compared to transcriptional profiling data previously 
generated by RNA-seq.  This RNA-seq dataset was also generated from 
experiments using A673 cells.  EF-regulated genes were identified by knocking 
down EF via shRNA (shEF) and comparing expression of genes in shEF cells to a 
control shRNA targeting luciferase (shLuc).  Differentially expressed genes in shEF 
versus shLuc cells were considered to be EF target genes. 
In the RNA-seq data, 7,081 genes were found to be differentially expressed 
upon knockdown of EF.  We found that only 1,457 of those differentially expressed 
genes contained EF-bound loci within 5 kb.  These data suggest that only 20.6% 
(1,457 out of 7,081) of genes regulated by EF are likely direct targets of EF (Figure 
3.4A).  Thus, the majority of EF-driven transcriptional misregulation is likely due to 




instance, when EF increases expression of NR0B1 by binding directly to a GGAA 
microsatellite in the NR0B1 promoter, increased levels of the NR0B1 transcription 
factor then transmit the effects of EF to an array of NR0B1 targets, which could 
themselves exert downstream effects on transcription of other genes (14). 
 These putative direct targets of EF are comprised of 696 (47.8%) EF-
downregulated and 761 (52.2%) EF-upregulated genes (Figure 3.4B).  These data 
further suggest that the mechanisms determining whether EF causes activation or 
repression of its targets likely depends upon other regulatory partners that interact 
with EF, such as the NuRD complex. 
 Interestingly, when we focused on the top 25 most upregulated and the 25 
most downregulated EF target genes (based on the fold change values determined 
via RNA-seq analyses) we observed a correlation between the presence of nearby 
GGAA repeats and EF-upregulated genes (Figure 3.4C).  Not one of the top 25 
EF-downregulated targets had a nearby GGAA microsatellite (Figure 3.4D).  These 
data further suggest that the mechanisms responsible for EF-mediated 
upregulation are distinct from the mechanisms responsible for EF-driven 
downregulation. 
 
3.3.4 CTCF binding sites overlap with EF binding 
 
sites in a minority of instances 
 
 ChIP-seq was also performed for the chromatin binding protein CTCF.  A 
total of 25,027 CTCF-bound loci were identified throughout the genome (Figure 
3.5A).  While CTCF sites could be found near the TSS of genes, the pattern was 




CTCF binding sites were identified in promoter regions (Figure 3.5C).  However, 
consistent with the known insulator and other regulatory roles of CTCF, the 
correlation of peaks to TSS sites was less prominent compared to EF sites, and 
the majority of CTCF-bound loci were found in intergenic regions (Figure 3.5C).   
 When the genomic coordinates of EF-bound loci were compared against 
the genomic coordinates of CTCF-bound loci, we found that only a small proportion 
of binding sites overlapped between the two datasets (Figure 3.5D).  This suggests 
that EF may, in a minority of cases, co-localize with CTCF and could potentially 
alter its insulator functions.  Additional study is needed to determine the nature, 




 The means by which EF transforms a healthy cell into a cancer cell has 
been – and continues to be – a subject of intense investigation.  Early 
breakthroughs identified the presence of EF and its role as a neomorphic 
transcription factor with oncogenic consequences.  Experiments revealed that EF 
could bind DNA and activate genes, and tumorigenesis was found to depend on 
the ability of EF to bind DNA and alter gene expression.  Continuing research has 
led to more detailed understanding of these mechanisms, and it has become even 
more clear that these processes are complex and nuanced.   
 Here we began an exploration of the localization of EF across the genome.  
Consistent with earlier studies using microarray and other technologies, we 
demonstrated that EF binds to both high-affinity ETS consensus sequences 




Importantly, we show that while EF-bound GGAA repeats appear to correlate more 
with activated targets of EF, some EF-repressed genes are also in close proximity 
to GGAA microsatellites.  These data indicate that DNA binding alone is not 
sufficient to explain whether EF upregulates or downregulates target genes.   
Indeed, these data suggest that local context at individual gene loci may 
play a role in determining the function of EF on that locus.  Such an interplay 
between EF and individual loci would presumably depend upon what other 
regulatory factors and complexes potentially are involved in existing regulatory 
systems for a given gene.  Work demonstrating the importance of complexes like 
NuRD, and epigenetic regulators such as LSD1, are consistent with this model 
(23,24).  Continuation of these studies will foster development of a more detailed 
understanding of how EF transforms a healthy cell into a cancer cell, and promises 
to inform future therapeutic strategies directed at the cellular and molecular level. 
  
3.5 Materials and Methods 
 
3.5.1 Chromatin immunoprecipitation 
 
Magnetic beads conjugated to anti-rabbit IgG (Dynabeads, ThermoFisher 
#11204D) were coated with either anti-FLI (Santa Cruz #sc-356), anti-CTCF 
(Santa Cruz, #sc-5916), or normal rabbit IgG (Santa Cruz, #sc-2027; negative 
control) antibodies.  Specifically, 100 µL of beads were added to 2 mL of dilution 
buffer [20 mM Tris, pH 7.9, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 20 mg/ml 
BSA plus protease inhibitor cocktail (Roche EDTA-free complete, Sigma 
#11836170001)] and 5 µg of antibody was added.  All ChIP procedures were 




mixtures were rotated overnight at 4° C.  
A673 cells were grown in 15-cm tissue culture plates until approximately 
90% confluency.  Cross-linking was then performed by adding 1 mL of 16% (w/v) 
methanol-free formaldehyde solution (ThermoFisher #28906) directly to 15 mL of 
culture medium on cells (final concentration: 1%) and gently rocking for 15 minutes 
at room temperature.  Cross-linking reactions were then quenched by adding 1 mL 
of 2 M glycine (final concentration: 125 mM) and rocking gently for 5 minutes at 
room temperature.  Culture medium was then discarded and cells were washed 
with 20 mL ice-cold PBS.  PBS was removed and 5 mL of ice-cold cell lysis buffer 
(50 mM HEPES-KOH, pH 8, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 10% 
glycerol, 0.5% NP-40, 0.25% Triton X-100) was added, and cells were dissociated 
from the plate by a cell scraper.  Cells and lysis buffer were collected and cells 
were rotated end over end for 10 minutes at 4° C, and then pelleted via 
centrifugation at 300 rcf and 4° C.  The cell pellet was then resuspended in 10 mL 
ice-cold wash buffer (10 mM Tris, pH 7.9, 1 mM EDTA, 0.5 mM EGTA, 200 mM 
NaCl) and pelleted again via centrifugation at 300 rcf and 4° C.  Cell pellets were 
then resuspended in 500 µL ice-cold nuclei lysis buffer (50 mM Tris, pH 7.9, 10 
mM EDTA, 1% SDS, 1X protease inhibitor cocktail) and subjected to sonication 
using a probe sonicator.  Cells were kept in ice during sonication, and sonication 
times and conditions were empirically determined by assessing DNA 
fragmentation using 10% agarose/TAE gel electrophoresis.  Optimal fragment size 
was between 100 and 400 bp (Figure 3.6A).  Following sonication, cell lysates 




cell extract was added to magnetic beads (pre-coated with antibody or normal IgG; 
250 µL of extract per ChIP reaction; one batch of extract is sufficient for 
approximately 4 ChIP reactions) and rotated overnight at 4° C.  The following day, 
beads were pelleted with a magnet, and four washes were performed by 5 minute 
rotations at 4° C.  IP washes were performed with increasing stringency; Wash #1: 
20 mM Tris, pH 7.9, 2 mM EDTA, 250 mM NaCl, 0.05% SDS, 0.25% NP-40; Wash 
#2: 20 mM Tris, pH 7.9, 2 mM EDTA, 500 mM NaCl, 0.05% SDS, 0.25% NP-40; 
Washes #3 & 4: 20 mM Tris, pH 7.9, 2 mM EDTA, 500 mM LiCl, 0.05% SDS, 
0.25% NP-40.  Beads were finally rinsed in TE buffer (10 mM Tris, pH 8, 1 mM 
EDTA) and beads were resuspended in sodium bicarbonate solution (final 
concentration: 1 mM) and treated with 2 µL of 10 mg/ml RNAse A for 20 minutes 
at 37° C.  Elution and cross-link reversal was performed by adding 10 µL of 20% 
SDS and incubating at 65° C overnight.  Eluted DNA was then collected via ethanol 
precipitation by adding 20 µL of 3M sodium acetate, 15 µL glycogen (20 mg/ml) 
and 500 µL of ethanol (200 proof), and incubating overnight at -20° C.  Precipitates 
were collected by centrifugation at 20,000 rcf for 20 minutes at 4° C, and rinsed 
twice with ice-cold 70% ethanol/water followed by centrifugation.  Pellets were air 
dried, and dissolved in 20 µL nuclease-free water.  Successful ChIP assays were 
verified by qPCR of known EF-bound loci near GSTM4 and NR0B1 (Figure 3.6B).  
Fold enrichment was determined by comparing to the normal IgG negative control 







3.5.2 Library construction and sequencing 
 Libraries were constructed using the NEBNext library prep kit for Illumina 
sequencing (New England BioLabs #E7645) and AMPure XP magnetic beads 
(Beckman Coulter #A63881) according to manufacturer instructions.  Unique index 
primers were selected for each ChIP and input sample to permit multiplexing on 
sequencing flowcells.  DNA concentrations were determined using Qubit dsDNA 
HS assay kit (ThermoFisher #Q32851) and enrichment of signal at target genes 
was confirmed by qPCR of library DNA.   
 High-throughput sequencing was performed at the High Throughput 
Genomics core facility at the Huntsman Cancer Institute.  Briefly, ChIP DNA 
libraries were sequenced by Illumina HiSeq 50 cycle single read sequencing, 
version 4.  Between 21 x 106 and 37 x 106 sequence reads were obtained for each 
sample, multiplexed on a single flowcell.   
 
3.5.3 Alignment to reference genome and  
sequence analysis 
Sequence data were aligned to the February 2009 (GRCh37/hg19) build of 
the human genome using Novoalign (Novocraft Technologies) (30).  Aligned 
sequence tracks were visualized using Integrated Genome Browser (IGB; BioViz) 
(31).   
 Identification of ChIP peak loci was performed using the ChIPSeq wrapper 
of applications in the USeq software package (32).  ChIP peaks were normalized 
to their corresponding input samples.   




Neighboring Genes) application in the USeq package, and the R application 
ChIPpeakAnno (33,34).  Overlaps between EF and CTCF ChIP-seq peaks was 
determined using the findOverlappingPeaks function in the ChIPpeakAnno 
package.  Venn diagrams were also produced using R.   
Other analyses (e.g., proximity of peaks to transcription start sites, genomic 
region annotations, and comparisons to transcriptional profiling/RNA-seq data) 
were performed and figures were generated using the ChIPSeeker package in R 
(35).  RNA-seq data were previously published, and are publicly available in the 
NCBI BioProject database, accession #PRJNA176544, and the Sequence Read 
Archive, accession #SRA059329 (24,36).  ChIP-seq data for EF and CTCF 
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Figure 3.1 EF ChIP-Seq identifies numerous binding site across the genome.  
A) EF ChIP-Seq peaks visualized across all chromosomes.  A total of 22,406 EF 
bound loci were identified by peak-calling algorithms (see Materials and Methods).  
These experiments were performed using A673 cells, which were derived from a 
female patient, and hence no peaks were mapped to the Y chromosome.  B & C) 
EF-bound loci are found predominantly within 1kb of the transcription start sites 
(TSS) of genes.  While EF binding sites can be found great distances from genes 
(not shown), a great number of EF-bound loci are found in promoter regions, 











Figure 3.2 EF binds high-affinity ETS-sites.  EF ChIP-Seq reveals peaks at 
high-affinity consensus sequences for ETS-family transcription factors 
[ACCGGAAGT(G/A)].  Representative tracks are shown: A) EF binds at the 5’ end 






Figure 3.3 EF binds GGAA repeats.  A & B) EF-bound GGAA repeats were 
observed near genes known to be upregulated by EF.  C & D) EF-bound GGAA 
repeats were also observed near genes known to be downregulated targets of EF, 





Figure 3.4 EF-binding at GGAA repeats is correlated with upregulation of 
neighboring genes.  A) 1,457 genes were found to be differentially expressed 
after EF knockdown and have EF-bound loci within 5kb.  This amounts to 20.6% 
of all genes identified by RNA-seq as differentially expressed after EF knockdown.  
B) Of these 1,457 genes, 761 (52.2%) are activated by EF, and 696 (47.8%) are 
repressed by EF.  C & D) The 25 genes with the greatest magnitude of change 
after EF knockdown (EF-activated or EF-downregulated) were investigated to 
determine presence of nearby EF ChIP-seq peaks.  Among EF-upregulated genes, 
68% had a GGAA microsatellite within 5kb of the TSS, compared to none of the 





Figure 3.5 CTCF ChIP-Seq reveals few loci where both EF and CTCF can bind.  
A) CTCF ChIP-Seq peaks visualized across all chromosomes.  A total of 25,027 
CTCF- bound loci were identified by peak-calling algorithms (see Materials and 
Methods).  These experiments were performed using A673 cells, which were 
derived from a female patient, and hence no peaks were mapped to the Y 
chromosome.  B) CTCF-bound loci can be found within 3 kb of the transcription 
start sites (TSS) of genes.  C) The majority of CTCF-bound loci were found in distal 
intergenic regions, although numerous sites are found in other regions, including 
promoters and introns.  D) Peaks in the CTCF ChIP-seq data did not overlap 
significantly with peaks from the EF ChIP-seq data.  2,059 peaks were omitted 
from the overlap analysis as some enriched regions originally counted as multiple 












Figure 3.6 Verification of ChIP procedure.  A) DNA fragmentation was verified 
after sonication by 10% agarose/TAE electrophoresis of fragmented DNA.  We 
aimed for a fragment size of 100-400 bp.  B) qPCR results showing enrichment at 
known EWS/FLI-bound targets.  NR0B1 and GSTM4 both have GGAA 
microsatellites just upstream of their TSS.  Primers were designed within the 
GGAA region and qPCR was performed to determine whether ChIPs were 
successful.  Enrichment was determined by comparing ChIP samples to IgG 














YOU ARE WHAT YOU EAT… OR ARE YOU? 
 
 
A preview article that accompanied publication of work demonstrating the 
biosynthetic program of cellular metabolism utilized by cells undergoing rapid 
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THE EWS/FLI FUSION PROTEIN IS REQUIRED FOR  
 







Ewing sarcoma is a bone malignancy driven by the fusion protein EWS/FLI 
(EF). EF functions as an aberrant transcription factor that misregulates the 
expression of thousands of genes. Previous work has focused principally on 
determining important transcriptional targets of EF, as well as characterizing 
important regulatory partnerships in EF-dependent transcriptional misregulation. 
Less is known, however, about EF-dependent metabolic changes or their role in 
Ewing sarcoma biology.  We determined the metabolic effects of silencing EF in 
Ewing sarcoma cells. Metabolomic analyses revealed distinct separation of 
metabolic profiles in EF-knockdown vs. control-knockdown cells. Mitochondrial 
stress tests demonstrated that knockdown of EF increased respiratory as well as 
glycolytic functions. Enzymes and metabolites in several metabolic pathways were 
altered, including de novo serine synthesis and elements of one-carbon 
metabolism. We found that phosphoglycerate dehydrogenase (PHGDH) is highly 
expressed in Ewing sarcoma, correlating with worse patient survival. PHGDH 




Interestingly, PHGDH modulation also led to elevated histone expression and 
methylation. These studies demonstrate that the translocation-derived fusion 
protein EF is a master regulator of metabolic reprogramming in Ewing sarcoma, 
diverting metabolites toward biosynthesis. These data further suggest that the 
metabolic aberrations induced by EF are important contributors to the oncogenic 
biology of these tumors. This previously unexplored role of EF as a driver of 
metabolic reprogramming expands the understanding of Ewing sarcoma biology, 




Ewing sarcoma is an aggressive malignancy that most often emerges from 
bone and bone-associated tissues of children and adolescents.  It is the second 
most common pediatric bone tumor; second only to osteosarcoma.  Surgical 
strategies have achieved very good outcomes for many of these patients.  But truly 
effective molecular therapies continue to evade discovery, translating to especially 
poor prognosis for patients who fall victim to metastasis or relapse (1).  Indeed, the 
rate of relapse after surgery is ~35%, and the probability of 5-year survival after 
relapse is ~20% (2,3).  Continued investigation of the molecular underpinnings of 
this disease is thus crucial, and has the promise of providing additional candidate 
therapies to these patients.    
Ewing sarcoma tumors are uniquely devoid of recurrent mutations in 
classical oncogenes or tumor suppressors (4).  Instead, oncogenesis of Ewing 
sarcoma is almost entirely due to the far-reaching consequences of a single 




chromosomal rearrangement generates an in-frame fusion product merging the 
EWSR1 and FLI1 genes, giving rise to the oncogenic fusion protein known as 
EWS/FLI (EF).  EF contains the N-terminal transcriptional regulatory domain of 
EWS and the DNA-binding domain of FLI1.  Interestingly, while EF can affect 
known targets of FLI1 by binding to canonical FLI1 binding sites, it also influences 
expression of genes that are not targets of FLI1 or EWSR1 (5,6).  Thus, EF is an 
aberrant transcription factor with neomorphic functions and tumorigenic 
consequences. 
The transcriptional reprogramming driven by EF has been well profiled (7–
15).  In-depth study of EF targets has revealed that this master regulator exerts its 
oncogenic effects on numerous processes, contributing to many of the hallmark 
capabilities of cancer cells.  These include: proliferation and growth (16,17), 
resistance to cell death (18), immortality (19), angiogenesis (20), invasion and 
metastasis (18,21), and evading immune destruction (22).  However, very little is 
known about how EF affects another characteristic feature of cancer cells – the 
pro-oncogenic reprogramming of cellular metabolism.  
Cancer cells characteristically adopt programs that modify substrate 
utilization and alter metabolite abundance in ways that support the biosynthetic 
requirements of these highly proliferative and resilient cells (23).  Evidence 
increasingly indicates that metabolic alterations observed in cancer are not mere 
spectator phenomena, but are active contributors to oncogenesis (23).  Significant 
interrelationships exist linking cellular metabolic processes to nuclear control, and 




cancer cells provides promising new opportunities for discovery of potentially 
actionable therapeutic targets.   
Currently, there is a paucity of data concerning the role of EF in altering 
metabolic processes in Ewing sarcoma.  Given its relatively low mutation burden 
compared to other cancers (4), Ewing sarcoma provides a unique model to study 
metabolic alterations that are important to oncogenesis.  Changes in cellular 
metabolism that result from EF transcriptional misregulation likely contribute 
directly to oncogenesis.  Thus, studying cellular metabolism in Ewing sarcoma 
promises to increase our understanding of metabolic reprogramming in general, 
and inform development of novel therapeutic strategies for Ewing sarcoma 
specifically.  With these goals in mind, we set out to investigate EF-driven 




5.3.1 EWS/FLI misregulates numerous genes  
involved in metabolism 
Transcription profiling of Ewing sarcoma cells has been previously 
performed by microarray and RNA-seq experiments after silencing EWS/FLI (EF) 
in A673 cells (7,25,26).  We analyzed data from a publicly available RNA-seq 
dataset wherein EF was silenced by shRNA (shEF) and compared to control 
knockdown (shLUC).  Our analysis identified 7,094 genes that are differentially 
expressed in shEF vs. control shLUC cells (gene lists found as Excel files in 
Supplemental Data).  We defined significant changes in expression as a fold 




exhibited increased expression, while 2,954 genes were less expressed.  Gene 
ontology (GO) analysis was performed on the list of all EF-misregulated genes, 
revealing metabolic processes (GO: 0008152) as the second most enriched GO 
term (2,058 genes; 33.7%) (Fig. 5.1A).  These genes were further subdivided into 
primary metabolic processes (GO: 0044238), revealing that the majority of these 
genes were involved in nucleobase-containing compound metabolism (GO: 
0006139) and protein metabolism (GO: 0019538) (Fig. 5.1B).   
To further assess whether EF significantly alters genes of metabolic 
importance, gene set enrichment analysis (GSEA) was performed comparing our 
dataset of differentially expressed genes in shEF cells to gene sets from the 
Molecular Signatures Database (MSigDB) (27).  Significant correlations were 
observed between differentially expressed genes and genes in the Hallmark-
Glycolysis gene set and the KEGG-Pathways in Cancer gene set (Fig. 5.1C & 1D).  
Significant correlations were also observed with gene sets of Hallmark-Reactive 
Oxygen Species, Hallmark-Epithelial-Mesenchymal Transition, but not in the 
Hallmark-Oxidative Phosphorylation gene set (Fig. 5.2A).   
 
5.3.2 Knockdown of EWS/FLI causes changes  
 
in cellular metabolism 
 
To more directly study whether EF alters cellular metabolism, we performed 
stress tests on glycolysis and mitochondrial function using the Seahorse XF96 
analysis system.  During the glycolysis stress test, addition of glucose and 
oligomycin caused greater increases of extracellular acidification rate (ECAR) in 




between shEF and shLUC cells throughout the glycolysis stress test (Fig. 5.3B).  
These data suggest that silencing of EF results in increased utilization of glucose 
by glycolysis (Fig. 5.2B).  Basal ECAR was not different between shEF and shLUC 
cells at the beginning of the glycolysis stress test, reflecting the lower glucose (10 
mM) conditions required for a glycolysis stress test (Fig. 5.3B).  However, in the 
mitochondrial stress test, glucose is present at typical cell culture levels (25 mM), 
allowing us to observe that basal ECAR is higher in shEF vs. shLUC cells (Fig. 
5.3C).  The apparent increase of glycolytic rate caused by EF knockdown is 
surprising, and is possibly explained by de-repression of hexokinase 1 (HK1) by 
shEF (Fig. 5.3E).  Indeed, uptake of 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-
yl)amino]-D-glucose (2-NBDG; a fluorescently-labeled analog of deoxyglucose) is 
elevated in shEF vs. shLUC A673 cells (Fig. 5.3F). 
Tests of mitochondrial respiration showed enhanced response to 
mitochondrial uncoupling by carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) in shEF vs. shLUC cells (Fig. 5.3D).  These data indicate 
that silencing EF results in increased maximal respiration and spare respiratory 
capacity, with no change in basal respiration, ATP production, proton leak, non-
mitochondrial respiration, and coupling efficiency (Fig. 5.2B). To additionally 
assess mitochondrial respiratory function, cells were treated with the membrane 
potential-sensitive Mitotracker Red FM dye.  Comparisons were made relative to 
a membrane potential-independent mitochondrial dye (Mitotracker Green).  
Consistent with increased maximal respiration and respiratory capacity, shEF cells 




(Fig. 5.3G).  Together, these data suggest that EF increases the proportion of 
glucose-derived carbon that is shunted away from oxidative metabolism consistent 
with a biosynthetic, pro-oncogenic metabolic program. 
 
5.3.3 EWS/FLI is required for global changes 
 
in metabolite abundance 
 
Global changes in metabolite abundance were assessed by performing 
steady-state metabolomics analyses comparing shEF with shLUC A673 cells.  
Examining metabolomic data by principal components analysis revealed that EF 
knockdown results in a distinct metabolic profile compared to control cells (Fig. 
5.4A & 5.3B).  Topological analysis of metabolites within metabolic pathways 
highlighted several metabolic pathways that were more significantly impacted by 
silencing of EF (Fig. 5.4C) (28,29).  Pathways significantly affected by EF silencing 
included alanine, aspartate, and glutamine metabolism, and glycine, serine, and 
threonine metabolism. 
Additionally, metabolomic profiling data were combined with transcription 
profiling data to perform analyses of pathways in which both metabolite abundance 
and gene expression were significantly altered in shEF vs. shLUC cells.  This 
allowed us to determine which pathways were impacted the most by shEF, 
potentially by altering expression of enzymes and metabolites in that pathway.  
Intriguingly, the enzymes of serine and glycine synthesis were found to be 
significantly downregulated by EF silencing in the RNA-seq dataset, and 
corresponding decreases in serine and glycine were observed in our metabolomic 




5.3.4 EWS/FLI upregulates expression of serine 
 
and glycine synthesis enzymes 
 
The de novo serine synthesis pathway is one way by which glycolytic 
intermediates can be shunted toward biosynthetic processes, and this has been 
implicated in many cancers (30,31). Specifically, phosphoglycerate 
dehydrogenase (PHGDH) commits the glycolytic intermediate 3-phosphoglycerate 
to serine and glycine synthesis, providing important precursors for protein, lipid, 
and nucleic acid synthesis.  Increased PHGDH has been linked to the oncogenic 
biology of other tumors (30,32).  In fact, PHGDH expression is higher in Ewing 
sarcoma than all other cancer cell lines in the Cancer Cell Line Encyclopedia (Fig. 
5.6A).   
In concordance with RNA-seq data, protein levels of PHGDH were 
decreased in shEF vs. shLUC cells (Fig. 5.7A).  Protein levels of phosphoserine 
aminotransferase (PSAT) and phosphoserine phosphatase (PSPH) – the two 
enzymes downstream of PHGDH in the serine synthesis pathway – were also 
lower upon silencing of EF (Fig. 5.7A).  Similar patterns of expression were 
observed for serine hyrdroxymethyltransferase (SHMT1 and SHMT2), which 
converts serine to glycine and feeds into one-carbon folate metabolism cycles, as 
well as dihydrofolate reductase (DHFR) and thymidylate synthetase (TYMS) – 
important enzymes in one-carbon folate metabolism cycles (Fig. 5.7B and Fig. 






5.3.5 PHGDH is elevated in high-risk  
Ewing sarcoma patients 
To explore correlations between PHGDH expression and clinical outcome, 
we used the SurvExpress tool to perform Cox survival analysis of a Ewing sarcoma 
dataset (33,34).  Patients who were categorized as high-risk had significantly 
higher expression of PHGDH and SHMT1/2 (Fig. 5.7C & D).  Similarly, higher 
expression of PSPH, DHFR, TYMS, MTHFD2, and SHMT2 was correlated with 
poorer survival in Ewing sarcoma patients (Fig. 5.6B & C).  Similar correlations 
were also observed between expression levels and event-free survival (data not 
shown).   
Furthermore, PHGDH expression was assessed in histological samples 
from Ewing sarcoma patients.  PHGDH staining was much higher in tumor (defined 
by IHC for CD99) than in adjacent normal tissue (Fig. 5.8A).  CD99 exhibited 
staining along cell surface boundaries, while PHGDH staining appeared diffusely 
cytoplasmic. 
 
5.3.6 PHGDH is required for proliferation and 
normal chromatin modification 
Inhibition of PHGDH function by NCT502 and NCT503 caused growth 
defects and cell death in Ewing sarcoma cell lines, including the EWS/ERG-
harboring TTC466 line (Fig. 5.8B-E).  This effect was less prominent in 293T or 
U2OS cells (Fig. 5.8F & G). This and previous data indicate that upregulated 
expression of serine synthesis and 1-carbon metabolism contributes importantly 




While the major product of PHGDH is 3 phosphohydroxypyruvate (3-PP) 
from 3-phosphoglycerate (3-PG), the enzyme also produces relatively small 
amounts of 2-hydroxyglutarate (2-HG) from α-ketoglutarate (Fig. 5.9A) (35).   2-
HG has been shown to be oncogenic in high amounts, typically resulting from 
neomorphic mutations of isocitrate dehydrogenase enzymes (35,36).  
Interestingly, we observed that 2-HG was lower in shEF vs. shLUC cells (Fig. 
5.9B), suggesting that EF might be driving elevated production of 2-HG via 
increased expression of PHGDH.   
To test whether elevated levels of 2-HG in Ewing sarcoma cells were due 
to PHGDH, we assessed 2-HG levels after inhibition of PHGDH function with 
NCT502.  2-HG was lower in cells treated by NCT502 vs. its inactive analog (Fig. 
5.9C).  Importantly, the levels of 2-HG in Ewing sarcoma cells were lower than 
previously observed in cells harboring mutations in isocitrate dehydrogenase (IDH) 
enzymes (37,38).  To test whether 2-HG generated from PHGDH had effects on 
DNA methylation, we silenced PHGDH expression and determined 5-
methylcytosine (5-mC) content of LINE-1 elements (a surrogate for bulk DNA 
methylation). However, knockdown of EF or PHGDH had no effect on 5-mC levels 
(Fig. 5.9D).  PSPH was also silenced to distinguish between serine synthesis and 
2-HG producing functions of PHGDH, and disruption of serine synthesis 
downstream of PHGDH also had no effect on 5-mC levels.   
To further assess whether modulation of PHGDH affects chromatin, we 
immunoblotted histone proteins.  This was performed with A673 cells, as well as 




cell line (UTES-14-01872) (Fig. 5.5C).  Interestingly, methylation of histone H3 at 
lysine (K) 9 and K27 was increased by PHGDH knockdown in UTES-14-01872 and 
TTC466 cells, but not in A673 cells (Fig. 5.9E & F).  Additionally, total histone 
protein was increased by PHGDH knockdown in two of the three cell lines.  These 
data raise the possibility of a role for PHGDH in chromatin regulation, possibly by 





EF has long been recognized as the primary oncogenic driver of Ewing 
sarcoma.  Overexpression of EF in NIH3T3 murine fibroblasts results in oncogenic 
transformation, and silencing EF expression in patient-derived cell lines results in 
a loss of tumorigenesis (8,39–48). However, effective therapeutic strategies 
directly targeting transcription factors have been notoriously elusive.  For this 
reason, studies of the biology of Ewing sarcoma have primarily focused on 
identifying important EF target genes, as well as the interacting partners EF 
requires to elicit its effects.  Indeed, numerous EF targets have been shown to be 
necessary, but not sufficient, for oncogenesis in these tumors (7,10,21,25,49–53).  
Unfortunately, many of these critical EF targets and partners lack enzymatic 
function and are themselves not susceptible to pharmacological modulation.  With 
this in mind, we sought to determine whether EF generates an oncogenic program 
of cellular metabolism by misregulating the transcription of genes encoding key 
metabolic enzymes. 




significant patterns of altered metabolic gene expression (Fig. 5.1).  Specifically, 
gene ontology analysis revealed significant alterations in the expression of genes 
involved in glycolysis, nucleobase-containing metabolic processes, and protein 
metabolism.  Consistent with a cancerous phenotype, Ewing sarcoma cells are 
hyperproliferative and require increased macromolecule synthesis to sustain 
accelerated growth and proliferation.  It has been shown that Ewing sarcoma cells 
are therefore vulnerable to replicative stress, and inhibition of DNA repair pathways 
has been explored as a therapeutic option for Ewing sarcoma (54,55).  
Additionally, EF-driven alterations in nucleobase-containing metabolic processes 
such as (NAD salvage) could be sensitive to inhibition and therapeutic exploitation 
(56).  The increased metabolic demands of rapid proliferation and growth could be 
exploited in similar ways. 
We also observed that EF knockdown resulted in increased maximal 
respiration and mitochondrial membrane potential (Fig. 5.3D & 5.2G).  This is in 
line with studies of other malignancies, wherein various oncogenic processes lead 
to a metabolic program of aerobic glycolysis – diverting metabolites toward 
pathways that are important for various kinds of macromolecule synthesis (23).  As 
more carbon is diverted to biosynthetic pathways from glycolysis, flux through the 
TCA cycle may decrease, resulting in oncogene-induced reduction in respiratory 
capacity, as suggested by our data. These findings reinforce the concept that such 
a shift away from oxidative metabolism is a characteristic feature of oncogenesis, 
important in all cancers, and not a spectator phenomenon merely correlating with 




oncogenic metabolic reprogramming, in addition to and as a consequence of 
transcriptional reprogramming. 
Surprisingly, we also observed an increase of glycolysis in shEF vs. shLUC 
cells (Fig. 5.3A & C).  Such observations appear to run contrary to the known 
glycolytic metabolism that predominates in the vast majority of cancer cells.  This 
unique phenomenon could be explained by transcriptional downregulation of 
genes important for glucose import or utilization.  Indeed, we observed that 
hexokinase 1 (HK1) is increased in shEF vs. shLUC cells (Fig. 5.3E).  In such a 
scenario, EF may restrict glucose entry into glycolysis, effectively reducing the 
cell’s ability to metabolize additional glucose (as seen in our Seahorse analysis 
data).  However, if this restriction is not so severe to cause cell death by starvation, 
glucose uptake may remain sufficient to fulfill cellular energy requirements.  
Simultaneously, EF upregulates genes of biosynthetic pathways such as de novo 
serine synthesis (Fig. 5.7A), resulting in an increased proportion of glycolytic 
intermediates being shunted into biosynthetic pathways.  Thus it may be possible 
to generate the net effect of oncogenic and biosynthetic reprogramming of 
metabolism by increasing the proportion of glucose-derived carbon shunted 
towards biosynthetic pathways, even in the face of EF-induced downregulation of 
HK1.  Additionally, considering that the putative cell of origin for Ewing sarcoma is 
a mesenchymal stem cell, and that EF is known to repress mesenchymal features, 
the baseline glycolytic metabolism of these stem cells may provide ample flexibility 
to be permissive to decreased HK1 within the context of oncogenic metabolic 




of current and future study. 
Our findings also suggest that EF drives global shifts in metabolite 
abundance in Ewing sarcoma cells (Fig. 5.4).  Integrating metabolomic and 
transcriptomic data enabled us to identify EF-driven upregulation of de novo serine 
synthesis via PHGDH as an important candidate for further study.  PHGDH is 
amplified in various tumors, and has been implicated previously in tumor biology 
(30,35,58).  PHGDH commits the glycolytic intermediate 3-PG to de novo serine 
synthesis, and EF-driven upregulation of PHGDH expression appears to be an 
important factor in diverting metabolites toward macromolecule synthesis (Fig. 
5.7A).  Increased de novo serine synthesis also may create a positive feedback 
loop whereby elevated levels of serine inhibit PKM2, enhancing entry of 
metabolites into the serine synthesis pathway via PHGDH (59,60).  While perhaps 
not a major oncogenic outcome of elevated serine synthesis, such a feedback loop 
could amplify the effects of such increases.  Whether such a phenomenon exists 
in Ewing sarcoma has not been tested.  Importantly, elevated expression of 
PHGDH also correlates with a poor prognosis in Ewing sarcoma patients, 
suggesting that these phenomena have important clinical implications (Fig. 5.7C).  
Our findings are similar to previous findings demonstrating upregulation of serine 
synthesis by other oncogenes.  PHGDH, PSPH, and PSAT are upregulated in 
some Myc-driven lymphomas (61).  Additionally, oncogene-driven transcriptional 
misregulation in other malignancies (e.g., HER2, SP1, NFY, NRF2, ATF4) has 
been shown to increase expression of enzymes of de novo serine synthesis (62–




synthesis similar to other malignancies, and further study is required to determine 
whether EF exerts its effects by co-opting any of the aforementioned regulatory 
factors. 
Downstream of de novo serine synthesis, conversion of serine to glycine is 
carried out by serine hydroxymethyltransferase (SHMT).  This reaction is coupled 
to the conversion of tetrahydrofolate to 5,10-methylenetetrahydrofolate, and is a 
major provider of 1-carbon units needed for multiple cellular functions (65–67).  
Our data suggest that EF is also driving upregulation of these processes, further 
establishing a pro-oncogenic, biosynthetic metabolic program in these cells (Fig. 
5.5H).  It is likely that this is also clinically relevant, as patients with high levels of 
SHMT also have worse overall survival (Fig. 5.7D). Together, these data also raise 
the interesting possibility of utilizing expression levels of metabolic enzymes such 
as PHGDH and SHMT to inform predictions of patient prognosis, or even using 
metabolic indices to define different patient populations.   
The nature of the relationship between patient survival and expression 
levels of these genes deserves further consideration.  Several hypotheses exist 
for why increased expression of these enzymes correlate with poorer prognosis.  
For instance, upregulation of de novo serine synthesis may contribute importantly 
to increased synthesis of glycine and cysteine.  Such a process would contribute 
more amino acids to meet the biosynthetic requirements of proliferative cancer 
cells.  Additionally, since glycine and cysteine both contribute to production of 
glutathione, increased serine synthesis also potentially contributes to greater 




conditions of increased ROS production, perhaps contributing to increased 
capacity to confront redox stress (68).  Furthermore, the conversion of serine to 
glycine contributes importantly to one-carbon metabolism and the folate cycle.  The 
de novo synthesis of adenosine, guanosine, and thymidylate requires one-carbon 
units derived from serine.  Thus, increased serine synthesis could contribute to 
greater nucleotide synthesis in general.  Upregulation of SHMT1/2 and TYMS is 
consistent with these hypotheses.  Upregulation of such processes could permit 
cancer cells to become more proliferative or aggressive, thus contributing to poorer 
prognosis in patients.  However, as these hypotheses have yet to be tested, more 
in-depth investigation is clearly needed. 
Upregulation of de novo serine synthesis and one-carbon metabolism has 
far-reaching consequences for cancer cells, as flux through these pathways is 
important for regulation of methyl donor (methionine) recycling and epigenetic 
states.  In addition, previous work has suggested that amplified PHGDH may play 
a role in cancer through production of 2-HG (69).  2-HG is a known oncometabolite 
when overproduced by neomorphic mutations in IDH enzymes (70–72).  
Intriguingly, our data also suggest that important links exist between de novo 
serine synthesis (specifically PHGDH) and nuclear processes.  We observed 
decreased amounts of 2-HG in shEF vs. shLUC cells (Fig. 5.9B & C).  However, 
the amounts of 2-HG generated by EF-induced upregulation of PHGDH are lower 
than levels seen in other malignancies with IDH mutations, and 2-HG likely has 
less of a role in Ewing sarcoma biology.  Additionally, IDH mutations are rare in 




produced by PHGDH may be sufficient to promote histone methylation, 
contributing to an oncogenic hypermethylation of histones and, possibly, DNA (69).  
However, our results suggest that this is not the case in Ewing sarcoma.  Rather, 
knockdown of PHGDH did not affect DNA methylation (Fig. 5.9D), but did cause 
significant increases in histone methylation (Fig. 5.9E & F).  Interestingly, these 
histone alterations were observed in EF-expressing cells (UTES-14-01872) as well 
as in TTC466 cells, which harbor the alternate translocation EWS/ERG (found in 
~10% of Ewing sarcomas) (74,75).  While the mechanisms responsible for these 
chromatin changes are unclear, we hypothesize that abundance of metabolites 
important for the function of other enzymes (either as substrates or cofactors) 
might play a role.  Future efforts are aimed at testing these hypotheses and further 
elucidating the mechanisms linking metabolism and nuclear control. 
Taken together, our findings demonstrate that EF drives metabolic 
misregulation, resulting in diversion of metabolites toward biosynthetic pathways 
in order to meet the increased demands of oncogenesis.  EF induces increased 
expression of PHGDH, PSAT, and PSPH, shunting glycolytic intermediates into 
serine and glycine synthesis, and contributing to 1-carbon metabolism through 
upregulated SHMT.  This and further study of the role of EF as a driver of 
oncogenic metabolism promises to reveal new actionable targets for therapeutic 
intervention.  Such efforts aspire to inform the development of hitherto elusive 







5.5 Materials and Methods 
 
5.5.1 Cell culture 
Cell lines expressing EWS/FLI (A673, UTES-14-01872; see Fig. 5.5B & C) 
or EWS/ERG (TTC466) were grown in 10%FBS/DMEM or 10% FBS/RPMI (RPMI 
1640 Glutamax; ThermoFisher), respectively.  DMEM (Corning) contained 25 mM 
glucose, 4 mM L-glutamine, and 1 mM sodium pyruvate.  Media were 
supplemented with 3 µg/ml puromycin for selection of shRNA-expressing cells.  
293T cells were grown in 10% FBS/DMEM.  Population doublings were assessed 
using a 3T5 growth assay as previously described (14).  A673 and TTC466 lines 
were validated prior to experimentation by STR analysis (Genetica DNA Labs).  
The patient-derived cell lines A673 and TTC466 were acquired from stocks 
maintained S. Lessnick.  UTES-14-01872 is a recently-derived cell line of Ewing 
sarcoma established in 2014 by S. Schiffman. 
 
5.5.2 Virus production, shRNA constructs,  
and infections 
EWS/FLI- and Luciferase-siRNA sequences were used previously for 
transcriptional profiling of Ewing sarcoma (7,25,49,76).  siRNA sequences for 
PHGDH and PSPH were designed using the Whitehead Institute siRNA Selection 
Program (77).  shRNA-encoding inserts containing these sequences were ligated 
into the pMKO.1p retroviral vector.  siRNA sequences are found in Supplemental 
Materials and Methods.  Retrovirus was produced by transfecting 293T cells with 
Optimem and Lipofectamine 2000, and viral supernatant was collected at 48h and 




at -80° C.  Infections were performed by adding viral supernatant (plus 8 µg/ml 
polybrene) to sub-confluent cultures.  Selection in puromycin-containing media 
was continued for 3 days, and puromycin efficacy was confirmed by observing cell 
death in uninfected cells.   
As EF is the primary oncogenic driver of Ewing sarcoma, most Ewing 
sarcoma cell lines do not tolerate its silencing well.  A673 cells are known to best 
tolerate EF knockdown.  Accordingly, we have had the most success using A673 
cells, and limited success performing such experiments in other lines. 
 
5.5.3 Mitotracker staining 
A673 cells expressing shLUC or shEF were seeded onto 1.5 borosilicate 
chambered coverglass slides (Thermo Fisher) and incubated overnight.  Media 
was replaced with phenol red-free DMEM containing 25 mM glucose, 1% 
Glutamax, 1% sodium pyruvate, 100 nM Mitotracker Red FM, 200 nM Mitotracker 
Green FM, and 5 µg/ml Hoechst stain (Thermo Fisher).  Cells were incubated in 
staining medium for 10 minutes, after which staining medium was removed and 
cells were washed twice with phenol red-free medium.  Cells were immediately 
imaged using a Zeiss Axio Observer Z1 microscope.   
Images were quantified using ImageJ software.  Three cells were selected 
in each of 5 high-power field images for a total of 15 quantified cells.  Integrated 
density measurements were taken for Mitotracker Red and Mitotracker Green 
channels for each cell with identical areas, and corrected total cell fluorescence 
(CTCF) was calculated for each channel as described previously (78).  CTCF 




mean fluorescence of background readings).   
 
5.5.4 Western blotting 
Whole cell extract (WCE) was prepared using RIPA buffer containing 
protease inhibitor cocktail (Sigma).  Total protein content was determined via BCA 
assay, and WCE was prepared for SDS-PAGE by adding Laemmli buffer.  
Immunoblotting was done using the following antibodies: Fli1 (Abcam, 1:1,000), 
PHGDH (Cell Signaling, 1:1,000), PSAT (Abcam, 1:1,000), PSPH (Abcam, 
1:1,000), SHMT1 (Cell Signaling, 1:1,000), SHMT2 (Cell Signaling, 1:1000), TYMS 
(Cell Signaling, 1:1,000), DHFR (Abcam, 1:1,000), HK1 (Abcam, 1:1000), 
H3K9me3 (Abcam, 1:1,000), H3K27me3 (Cell Signaling, 1:1,000), Histone H3 
(Abcam, 1:5,000), α-tubulin (Cell Signaling, 1:5,000), β-actin (Sigma, 1:5,000).   
 
5.5.5 Immunohistochemistry 
Procedures for immunohistochemistry (IHC) are previously described (79–
81).  Briefly, paraffin was removed and tissue was subjected to high pressure 
antigen retrieval (Vector Unmasking Solution; Vector Laboratories, Burlingame, 
CA). Samples were incubated in primary antibody (PHGDH, Cell Signaling) 
overnight at 4°C. Secondary antibodies, raised in donkey (Jackson 
Immunoresearch, West Grove, PA), were used at a dilution of 1:250 at room 
temperature for 1-hour. Vectastain reagents and diaminobenzidine (DAB) (Vector 
Laboratories) were used to develop IHC. Images were subsequently taken on a 
Zeiss Axio Observer Z1 microscope. Tissue samples from human patients were 




Review Board.  
 
5.5.6 PHGDH inhibition, 2-HG and %5-mC 
The PHGDH inhibitors NCT502 and NCT503 (Cayman) and the inactive 
control molecule called PHGDH-inactive (Cayman) were reconstituted in DMSO.  
Final concentrations of inhibitors were 3.7 µM, 18.5 µM, and 37 µM for PHGDH-
inactive and NCT502; and 2.5 µM, 12.5 µM, and 25 µM for NCT503.  These 
concentrations were chosen to achieve maximal levels of inhibition at the highest 
doses based on previously published IC50 data (82).   
Global 5-methylcytosine levels were assessed using the Global DNA 
Methylation Assay – LINE1 (Active Motif).  D-2-hydroxyglutarate was quantified 
using a colorimetric D2HG assay kit (BioVision).  All procedures were carried out 
as indicated by the manufacturer. 
 
5.5.7 Analysis of functional metabolism via 
seahorse XFe96 analyzer  
Cells were seeded into 96-well format Seahorse analyzer plates 24 hours 
prior to performing Seahorse experiments.  We performed side-by-side Mito Stress 
Tests and a Glycolysis Stress Tests in 96-well format using the XF96e analyzer. 
The Mito Stress Test was performed in standard assay media (DMEM, 25 mM 
Glucose, 1 mM pyruvate, 2 mM Glutamine, pH 7.4) with the final concentrations of 
drugs as follows [Oligomycin: 2 µM; carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP): 2 µM; Rotenone: 0.5 µM; Antimycin A: 0.5 µM]. Assay 




min mixing, 0 min waiting, and 3 min measuring).  Data were normalized to cell 
number because morphological changes that result from EF silencing potentially 
confound normalization to total cellular protein (Fig. 5.2D) (57). The Glycolysis 
Stress test was performed in standard assay media (DMEM, 2 mM Glutamine, pH 
7.4) and the following final concentrations (glucose: 10 mM; Oligomycin: 2 µM; 2-
deoxy-glucose: 50 mM). Results were normalized as above and analyzed in WAVE 
software and processed through the XF Mito Stress Test Report and Glycolysis 
Stress Test Generators. All statistics were generated through GraphPad Prism 7 
using unpaired two-tailed student t-tests.  
 
5.5.8 Gene ontology, geneset enrichment analysis, 
and survival-expression analyses 
Gene ontology analysis was performed on lists of differentially expressed 
genes from RNA-seq data (Lg2Rto: 0.585; AdjP≥10).  Gene lists and data are 
available in Supplemental Data.  Methodology of the PANTHER gene ontology 
platform and gene set enrichment analysis (GSEA) are described elsewhere 
(27,83,84).  Ewing sarcoma patient survival data were compared with gene 
expression by analyzing a publicly available dataset (GSE17679) with the 
SurvExpress online tool (33,34).  Risk groups were defined by prognostic index, 
with low-risk being defined as less than the median prognostic index, and high-risk 







5.5.9 RNA-Seq dataset 
RNA-Seq of A673 cells treated with shLUC or shEF was previously 
performed (25,26).  The datasets we acquired are publicly available in the NCBI 
BioProject database, accession # PRJNA176544, and the Sequence Read 
Archive (SRA059329).  We re-analyzed these data to determine differential 
expression analysis using USeq (useq.sourceforge.net) version 8.8.3.  Lists of 
differentially expressed genes are provided in Supplementary Data. 
 
5.5.10 Steady-state metabolomics 
All GC-MS analysis was performed with a Waters GCT Premier mass 
spectrometer fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 
autosampler.  Dried samples were suspended in 40 µL of a 40 mg/mL O-
methoxylamine hydrochloride (MOX) in pyridine and incubated for 1 hour at 30°C.  
To autosampler vials was added 25 µL of this solution. 40 µL of N-methyl-N-
trimethylsilyltrifluoracetamide (MSTFA) was added automatically via the 
autosampler and incubated for 60 minutes at 37°C with shaking.  After incubation, 
3 µL of a fatty acid methyl ester standard (FAMES) solution was added via the 
autosampler then 1 µL of the prepared sample was injected to the gas 
chromatograph inlet in the split mode with the inlet temperature held at 250°C. A 
10:1 split ratio was used for analysis. The gas chromatograph had an initial 
temperature of 95°C for 1 minute followed by a 40°C/min ramp to 110°C and a 
hold time of 2 minutes.  This was followed by a second 5°C/min ramp to 250°C, a 
third ramp to 350°C, then a final hold time of 3 minutes. A 30 m Phenomex ZB5-5 




separation. Helium was used as the carrier gas at 1 mL/min. Due to the high 
amounts of several metabolites, the samples were analyzed once more at a 10-
fold dilution. Data were collected using MassLynx 4.1 software (Waters).  
Metabolites were identified and their peak area was recorded using QuanLynx.  
These data were transferred to an Excel spread sheet (Microsoft, Redmond WA). 
Metabolite identity was established using a combination of an in-house metabolite 
library developed using pure purchased standards and the commercially available 
NIST library.  Metabolomic data were further analyzed using MetaboAnalyst 3.0 
(28,29,85–89). 
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Figure 5.1  EWS/FLI exerts significant effects on expression of genes 
important for metabolism.  A. Gene ontology analysis of 5,698 EWS/FLI-
regulated genes from publicly available RNA-seq data using the PANTHER GO-
Slim Biological Process annotation dataset.  Threshold of significance for 
differential expression was log2(ratio) ≥ 0.585 and AdjP ≥ 10.  Of these, 1,920 
(33.7%) were annotated as metabolic processes (GO: 0008152).   B. Among these 
metabolic processes (GO: 0008152), genes annotated as primary metabolic 
processes (GO: 0044238) were mostly involved in nucleobase-containing 
compound metabolism (GO: 0006139) and protein metabolism (GO: 0019538).  C 
& D.  Gene set enrichment analysis comparing a rank-ordered dataset (ranked by 
AdjP) of EWS/FLI knockdown RNA-seq data to the gene sets Hallmark-Glycolysis 
and KEGG-Pathways In Cancer, available from the Molecular Signatures 
Database (MSigDB) version 5.2.  Differentially expressed genes (blue shaded 
region) in shEF vs. shLUC correlate significantly with genes important for 














Figure 5.2  EWS/FLI affects glycolytic and oxidative metabolism.  A. Gene set 
enrichment analysis comparing a rank-ordered dataset (ranked by AdjP) of 
EWS/FLI knockdown RNA-seq data to the gene sets Hallmark-Epthelial-
Mesenchymal Transition, Hallmark-Oxidative Phosphorylation, Hallmark-Reactive 
Oxygen Species, available from the Molecular Signatures Database (MSigDB) 
version 5.2.  Differentially expressed genes in shEF vs. shLUC are indicated by 
the blue shaded region.  NES = normalized enrichment score.  B. Results of 
glycolysis stress test.  C.  Results of mito stress test.  D. Photomicrograph of A673 
cells with shLUC and shEF, showing larger cells in shEF vs. shLUC.  Scale bars 
are 100 µm.  E. FPKM values from RNA-seq data, indicating an increase in 












Figure 5.3  Silencing EWS/FLI results in functional metabolic changes.  A & 
B.  Glycolysis stress tests demonstrate an increased extracellular acidification rate 
(ECAR) in response to a glucose bolus in shEF vs. shLUC A673 cells.  No 
difference was seen in oxygen consumption rate in the glycolysis stress test.  C & 
D.  Basal ECAR is higher in shEF vs. shLUC cells, a reflection of different basal 
glucose concentrations in different test media.  Mito stress tests reveal increased 
oxygen consumption rate (OCR) after treatment with the FCCP mitochondrial 
uncoupler, indicating increased maximal respiration in shEF vs. shLUC A673 cells.  
Basal respiration was similar between groups.  E.  Hexokinase 1 (HK1) was 
increased in A673 and UTES-14-01872 cells after EF knockdown.  F. Uptake of 
the fluorescent glucose molecule 2-NBDG was increased in shEF vs. shLUC cells, 
as measured by flow cytometry.  G.  Mitotracker red signal was elevated in shEF 
vs. shLUC cells, suggesting increased mitochondrial membrane potential.  A 
representative image from A673 cells is shown, and quantification was done on 3 
cells from each of 5 high-power field images, shown as the corrected total cell 











Figure 5.4  The global profile of cellular metabolite abundance is altered by 
EWS/FLI.   A. Principal components analysis of metabolite abundance data 
(assessed by GC-MS) demonstrates distinct metabolic profiles in shEF vs. shLUC 
A673 cells.   B. Hierarchichal clustering of differential metabolite abundance after 
EF knockdown was done by Euclidean distances and a Ward statistic.  Metabolite 
abundances cluster into two distinct groups corresponding to shEF and shLUC 
conditions.  Serine, glycine, and 2-hydroxyglutarate are indicated by green 
arrowheads.  C. Topological analysis of metabolite data was performed by 
MetaboAnalyst 3.0.  Circle color represents p value and node size represents 
pathway impact value.  Pathway impact is calculated as the cumulative percentage 






Figure 5.5  EWS/FLI affects metabolic pathways and enzyme levels.  A.  
KEGG pathway results from Metaboanalyst comparisons of metabolite changes 
and gene expression changes in the pathways of glycine, serine, and threonine 
metabolism.  Elements that change are indicated in yellow.  B & C.  Western blots 
of EF in A673 and UTES-14-01872 cells, indicating expression of EF is decreased 
in shEF vs. shLUC.  D & E.  Western blots of SHMT2, showing decreased 
expression after EF knockdown.  F & G.  PHGDH is decreased after EF knockdown 
in other Ewing sarcoma cell lines, although knockdown is more difficult to achieve 











Figure 5.6  Serine synthesis and 1-carbon enzymes are highly expressed in 
high-risk Ewing sarcoma patients.  A. Plot from the Cancer Cell Line 
Encyclopedia (CCLE) indicating that Ewing sarcoma highly expresses PHGDH, 
more than other cancer cell lines.  B & C.  SurvExpress plots of enzymes of de 
novo serine synthesis and key enzymes of 1-carbon metabolism.  Percent overall 
survival is plotted, correlating expression of these genes with patient outcome.  CI 








Figure 5.7  Key enzymes of serine and glycine synthesis, and 1-carbon 
metabolism, are altered by silencing EWS/FLI.  A. Western blots of enzymes of 
serine synthesis in A673 and UTES-14-01872 cells treated by shEF and shLUC.  
PHGDH, PSAT, and PSPH are lower in shEF vs. shLUC.  B. SHMT1, DHFR and 
TYMS are also decreased in A673 and UTES-14-01872 cells after EF knockdown.  
C & D. SurvExpress analysis of overall survival of patients correlated with 
expression of PHGDH, SHMT1 and SHMT2, demonstrating higher expression 







Figure 5.8  PHGDH is high in Ewing sarcoma tumors, and is important for 
cell viability.  A. Immunohistochemistry of CD99 and PHGDH in Ewing sarcoma 
tumors from a Ewing sarcoma patient.  Cell surface staining of CD99 is diagnostic 
for Ewing sarcoma.  Cytosolic staining of PHGDH closely correlates with regions 
of tumor, indicating elevated PHGDH levels in tumor vs. adjacent tissue.  B & C. 
PHGDH inibition in A673 cells by NCT502 and NCT503 causes decreased cell 
growth and eventual cell death.  D & E.  PHGDH inhibition also impaired cell growth 
of TTC466 cells.  F & G.  High-dose treatment of osteosarcoma cells (U2OS) and 
293T cells show some growth defect, but not as much as in Ewing sarcoma cell 
lines.  H. Diagramatic representation of serine/glycine synthesis and 1-carbon 
metabolism pathways that are decreased by EF knockdown.  Enzymes are green 
text and metabolites are black text.  Blue arrows indicate enzymes or metabolites 
that were observed as decreased in shEF vs. shLUC cells.  Nucleotide and folate 









Figure 5.9  Modulation PHGDH causes decreased 2-hydroxyglutarate, and 
altered expression and methylation of histones.  A. Diagramatic representation 
of PHGDH enzyme function.  PHGDH primarily catalyzes converion of 3-phospho-
D-glycerate (3-PG) to 3-phosphoonoxypyruvate (3-PP), but also produces a minor 
product via conversion α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG).  
KEGG reaction numbers are indicated.  B & C. 2-hydroxyglutarate abundance as 
measured by GC-MS is lower in shEF vs. shLUC A673 cells.  Inhibition of PHGDH 
by NCT-502 also decreases levels of 2-HG in A673 cells.   D.  LINE-1 methylation, 
a surrogate of bulk DNA methylation, is not different in shEF, shPHGDH or 
shPSPH vs. shLUC cells.  E & F.  In UTES-14-01872 and TTC466 cells, 
knockdown of PHGDH results in increased levels of histone H3 and increased 
methylation of H3 histones at lysine 9 and 27. This was not seen in A673 cells.  
A673 and UTES-14-01872 cell lines express EWS/FLI; TTC466 cells express the 
EWS/ERG fusion protein.  For H3K9me3 and H3K27me3, normalization to actin is 
shown in black beneath the respective bands; normalization to total H3 is shown 








CONCLUSIONS AND OUTLOOK 
 
 
 The development of a targeted molecular therapy for Ewing sarcoma 
remains an elusive goal.  Despite the fact that these tumors are driven by a single 
master regulator of oncogenesis, directly targeting EWS/FLI has been 
unsuccessful.  Transcription factors are notoriously difficult to modulate 
pharmacologically, and delivery of RNA interference-based therapeutics has 
proven to be far from trivial.  New technologies may provide new hope for targeting 
EWS/FLI directly, but compelling pre-clinical data have yet to be seen.   
 Amid such a dearth of methods capable of being directed against the 
principal driver of these tumors, researchers have looked downstream of EWS/FLI 
in search of targets that could be exploited therapeutically.  While most of these 
efforts have focused on transcriptional regulation, epigenetic modification, and 
other nuclear processes, little attention has been focused on metabolic pathways.  
Indeed, metabolic systems that are co-opted or altered by the presence of 
EWS/FLI might include targetable enzymes that could be modulated by new 
therapies.  An EWS/FLI-specific metabolic program could provide a targetable 
surrogate for EWS/FLI itself, providing a way to specifically destroy EWS/FLI-





 The work presented herein represents some of the first steps toward 
understanding the metabolic derangements that occur as a result of the t(11;22) 
translocation.  Further study of the alterations in carbon flux through various 
metabolic pathways will be a crucial next step in these investigations.  More in-
depth analysis of these processes using metabolic flux analysis and other 
techniques will provide crucial information and a higher-resolution understanding 
of these processes.  Such research may reveal idiosyncratic metabolic programs 
unique to Ewing sarcoma, and provide novel treatment opportunities.   
 Further experiments such as these are currently being designed and carried 
out by several groups.  As researchers push deeper into the realm of cellular 
metabolism in Ewing sarcoma, there is great potential for discovery.  Future 
insights will not only provide a better view of the metabolic alterations that promote 
cancer formation, but they will provide hope to patients and their families that better 
therapies – and possibly even cures – might one day be found. 
  
